The global autosomal dominant polycystic kidney disease (ADPKD) treatment market is on track for significant growth, with a projected valuation of US$ 1,197.3 million in 2023. According to recent market analysis, this sector is expected to expand at a compound annual growth rate (CAGR) of 5.97% from 2023 to 2033, ultimately reaching US$ 2,140 million.
The anticipated growth of the ADPKD treatment market is driven by increased awareness of the disease, advancements in therapeutic options, and a growing emphasis on improving patient outcomes.
Key Market Drivers:
- Increased Awareness of ADPKD: Rising awareness about autosomal dominant polycystic kidney disease among healthcare professionals and patients is essential for timely diagnosis and treatment. Educational initiatives and advocacy are playing a crucial role in promoting understanding of the condition and its impact on patients.
- Advancements in Therapeutics: The development of novel treatment options and therapies for ADPKD is contributing to market expansion. Innovative medications and management strategies are enhancing patient care and helping to slow disease progression.
- Focus on Patient Outcomes: There is an increasing emphasis on improving patient outcomes and quality of life for those affected by ADPKD. This focus is driving demand for effective treatments and comprehensive management plans tailored to individual needs.
Regional Insights: North America is expected to dominate the ADPKD treatment market, supported by advanced healthcare infrastructure and significant investment in research and development. Europe is also projected to hold a substantial share, while the Asia-Pacific region is anticipated to experience rapid growth due to improving healthcare access and rising awareness of kidney diseases.
Market Outlook: As the awareness of autosomal dominant polycystic kidney disease grows and treatment options continue to evolve, the ADPKD treatment market is well-positioned for steady growth over the next decade. With ongoing advancements in therapeutics and a commitment to improving patient outcomes, the market is set to thrive through 2033.
Drug companies stand to benefit from market exclusivity for a set length of time, as well as clinical trial tax benefits and treatment assistance, which can help increase the market. Technological advances and the development of a diverse range of medications are also likely to drive market expansion, allowing physicians to better support Autosomal Dominant Polycystic Kidney Disease patients. Government activities aiming at improving knowledge of Autosomal Dominant Polycystic Kidney Disease Treatment, such as those done by the Polycystic Kidney Foundation, are also projected to support market expansion.
However, the high cost of Autosomal Dominant Polycystic Kidney Disease Treatment remains a significant impediment, as does the industry’s scarcity of trained professionals.
Key Takeaways
- With a market share of over 39.5% by the end of the forecast period, North America is expected to lead the industry.
- Over the forecast period, East Asia’s market is expected to grow at the fastest rate of 6.2%.
- By the end of the projection period, pain and inflammation are estimated to account for 37.4% of the market.
- Hospital pharmacies are expected to dominate the market by 2033, accounting for 54% of the market.
“One primary factor that will lead to the expansion of the global polycystic kidney disease drug market is the increasing availability of favourable reimbursement policies. Off-label medications are majorly given to people with polycystic kidney disease,” comments an FMI analyst.
Market Competition
The autosomal dominant polycystic kidney disease treatment market is intesely competitive and consists of several industry players. These players are developing novel delivery systems for treating Autosomal dominant polycystic kidney disease treatment. This is estimated to propel Autosomal dominant polycystic kidney disease treatment market. The key players in this industry are: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics, Inc, PanoTherapeutics, Inc, and Exelixis, Inc.
To stay in the forefront of highly competitive market, the key market players are focusing on expanding their geographical reach and investing in product development. The practice of adopting organic as well as inorganic strategies by the players help the polycystic kidney disease treatment market to grow at a significant growth rate. This is anticipated to fuel the global Autosomal dominant polycystic kidney disease treatment market.
- In July 2022, Grupo Olmos which is a provider of renal care solutions, declared that the company had acquired renal care business of Diaverum, a renal healthcare provider, that operates in Argentina. This acquisition will strengthen the renal product portfolio of the company.
- In 2020, Palladio Biosciences declared about the first patient of autosomal dominant polycystic kidney disease dosed with lixivaptan which is a novel vasopressin V2 antagonist. They assured the safety of lixivaptan in these patients who earlier discontinued therapy with tolvaptan due to liver toxicity.
- In March 2019, Aster Hospitals, the biggest private healthcare service providers operating in multiple GCC states, declared that it had launched an awareness and screening initiative to promote the prevention of chronic kidney disease through education, awareness, and early diagnosis.
- In August 2022, Bayer announced launch of finerenone drug to treat chronic kidney disease associated with type-2 diabetes in India.
- In July 2022, Health Canada accepted GlaxoSmithKline’s new drug submission for daprodustat which is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia of chronic kidney disease
Key Companies Profiled
- Otsuka Pharmaceutical
- Sanofi S.A
- Reata Pharmaceuticals
- Galapagos N.V
- Janssen Pharmaceuticals
- Regulus Therapeutics
- Xortx Therapeutics
- AceLink Therapeutics Inc.
- Pano Therapeutics, Inc.
- Exelixis, Inc.
Key Segments Profiled in the Autosomal Dominant Polycystic Kidney Disease Treatment Industry Survey
By Treatment Type:
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
